NCT07639567

Brief Summary

This study aims to develop and validate a deep learning-based opportunistic multi-cancer screening system using routine non-contrast chest-abdomen-pelvis CT examinations, including CHANCE-Breast, CHANCE-Liver, CHANCE-Kidney, and CHANCE-Bladder, for the early detection of breast, liver, kidney, and bladder cancers. In addition, the study will assess a human-AI collaborative framework to determine its potential for improving cancer detection and reducing missed diagnoses in clinical practice.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100,000

participants targeted

Target at P75+ for all trials

Timeline
24mo left

Started Jul 2026

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 5, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 10, 2026

Completed
21 days until next milestone

Study Start

First participant enrolled

July 1, 2026

Expected
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2028

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2028

Last Updated

June 10, 2026

Status Verified

June 1, 2026

Enrollment Period

2 years

First QC Date

June 5, 2026

Last Update Submit

June 5, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • diagnostic sensitivity

    1.5 years

Study Arms (3)

Positive Group / Malignant Cohort

Negative Control Group I / Benign Cohort

Negative Control Group II / Healthy Cohort

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with a confirmed diagnosis of the target malignancy who received treatment.

You may qualify if:

  • Patients with a confirmed diagnosis of the target malignancy who received treatment at our institution;
  • Diagnostic-quality CT images without substantial metal or motion artifacts and with complete anatomical coverage of the target organ (breast, liver, kidney, or bladder);
  • Availability of complete pre-treatment non-contrast CT imaging data.

You may not qualify if:

  • Non-diagnostic image quality;
  • Absence of a definitive reference-standard diagnosis;
  • Incomplete clinical or imaging data.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Union Hospital,Tongji Medical College,Huazhong University of Science and Technology

Wuhan, Hubei, 430000, China

Location

MeSH Terms

Conditions

Neoplasms

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Director

Study Record Dates

First Submitted

June 5, 2026

First Posted

June 10, 2026

Study Start (Estimated)

July 1, 2026

Primary Completion (Estimated)

July 1, 2028

Study Completion (Estimated)

July 1, 2028

Last Updated

June 10, 2026

Record last verified: 2026-06

Locations